President & CEO Update

Alzheimer's Association

This message is sent to all Alzheimer's Association and Alzheimer's
Impact Movement board members, all Alzheimer's Association staff, and
volunteers and supporters of AIM and the Alzheimer's Association.

I am disappointed to report that a Food and Drug Administration (FDA)
Advisory Committee
recommended today that a new drug not be approved by the FDA to treat
Alzheimer's. This is not the end of the road. It is one step in
the FDA review process.

The Alzheimer's Association will continue to advocate for the
FDA to approve aducanamab.

In her testimony before the committee, Alzheimer's Association
Chief Strategy Officer, Dr. Joanne Pike, outlined the need to offer
relief to the millions of Americans, those with the disease and their
caregivers, who face the crushing realities of Alzheimer's.

Though the treatment would potentially delay decline, not stop onset
or progression, given the devastating toll of Alzheimer's, we
believe the publicly-released data on aducanumab justify FDA approval,
accompanied by a Phase 4 post marketing surveillance study.

The alternative - an additional Phase 3 trial - would deny
access up to four years. A four-year delay is too long for too many
- those who have the disease and their caregivers.

We have never before been this close to approval of a drug for
Alzheimer's that could change the progression of the disease,
not just the symptoms.

Again, the Alzheimer's Association will continue to advocate for
approval.

I will share more news with you when the FDA makes its final decision.
As always, thank you for everything you do to advance our mission to
make a difference for others - today and tomorrow.

Harry Johns Signature

Harry Johns
Chief Executive Officer

CONNECT WITH US

Facebook

Twitter

Pinterest

Blog

[link removed]
[link removed]
[link removed]
[link removed]

Alzheimer's Association

Alzheimer's Association

225 N. Michigan Ave., FL 17, Chicago, IL
60601

800.272.3900 | alz.org

tel:800.272.3900
[link removed]

© 2020 Alzheimer's Association. All rights
reserved. Alzheimer's Association is a not-for-profit 501(c)(3)
organization.

Contact Us
|
Privacy Policy
|
Unsubscribe

[link removed]
[link removed]
[link removed]



To unsubscribe from all future email, paste the following URL into your browser:
[link removed]